The stock of Actinium Pharmaceuticals Inc (ATNM) has gone down by -1.65% for the week, with a -19.21% drop in the past month and a 25.19% rise in the past quarter. The volatility ratio for the week is ...

Health care Over 1 million Texas children dropped from ... Education Frisco ISD faces $30.8M shortfall in 2024-25 ... Dining Check out 6 restaurants that recently opened ... Texas Legislature ...

The PGA of America has blessed Frisco. Now, everyone wants in on the development action. The suburban Dallas boomtown’s latest development will be a 242-acre mixed-use project from Fort Worth ...

A man from Austin is accused of starting a trash fire outside a home in Frisco, and is considered a person of interest in a devastating fire a few miles away. Jonathan Webb, 29, from Austin is ...

Editorial note: Homefront (defined in the Disclosure below) may earn a commission from affiliate partner links featured on our site. This commission does not influence our editors' opinions or ...

This prediction is currently active. The BUY prediction by bundfuture is currently unchanged from the start price. This prediction currently runs until 19.04.25. The prediction end date can be changed ...

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have ...

Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple ...

Four candidates are vying for two seats on the Frisco City Council in the upcoming May 4 election. For the Place 1 seat, incumbent John Keating is going up against candidate Mark Piland. For the ...

NEW YORK - Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM) has announced promising results from the Phase 3 SIERRA trial of Iomab-B, a targeted radiotherapeutic, at the 50th Annual ...

NEW YORK - Actinium Pharmaceuticals (NYSE: ATNM ), Inc. (NYSE AMERICAN: ATNM) has announced promising results from the Phase 3 SIERRA trial of Iomab-B, a targeted radiotherapeutic, at the 50th Annual ...